ATRA
Atara BiotherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The FDA-discussed path toward a tab-cel BLA resubmission and a stated mid-2027 runway create asymmetric upside if the regulatory update is constructive and the submission advances. [#PR-EARNINGS-2026-05-13]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.1.
What can break
Cash runway depends on operating efficiencies and financing proceeds, with dilution risk.
Momentum
95
Value
60
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.00 · Bear $4.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $13.67
Why
Momentum95 · Δ7d -1.1
Value60 · Δ7d -0.0
Sentiment38 · Δ7d -8.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-4.0
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.0
Sentiment
38
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.6
Δ21d
-8.0
Why this grade
Composite grade A. Momentum 95.2 / Value 59.8 / Sentiment 38.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$74.7M
Beta
-0.41
Shares Out
9.01M
P/E (TTM)
7.7
P/S (TTM)
0.80
P/FCF (TTM) · Derived
-3.59
Rev YoY
-99.5%
EPS YoY
-108.4%
Gross Margin
+96.1%
Op Margin
+17.3%
Net Debt
$44.32M
Current Ratio
2.16
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology